IN2014CN02591A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02591A
IN2014CN02591A IN2591CHN2014A IN2014CN02591A IN 2014CN02591 A IN2014CN02591 A IN 2014CN02591A IN 2591CHN2014 A IN2591CHN2014 A IN 2591CHN2014A IN 2014CN02591 A IN2014CN02591 A IN 2014CN02591A
Authority
IN
India
Prior art keywords
etanercept
combination
present
fragmentation
arginine
Prior art date
Application number
Other languages
English (en)
Inventor
Mark Manning
Brian Murphy
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of IN2014CN02591A publication Critical patent/IN2014CN02591A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
IN2591CHN2014 2011-10-18 2012-10-18 IN2014CN02591A (enrdf_load_html_response)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09
PCT/US2012/060748 WO2013059412A1 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols

Publications (1)

Publication Number Publication Date
IN2014CN02591A true IN2014CN02591A (enrdf_load_html_response) 2015-06-26

Family

ID=48136153

Family Applications (3)

Application Number Title Priority Date Filing Date
IN2592CHN2014 IN2014CN02592A (enrdf_load_html_response) 2011-10-18 2012-10-18
IN2591CHN2014 IN2014CN02591A (enrdf_load_html_response) 2011-10-18 2012-10-18
IN2527CHN2014 IN2014CN02527A (enrdf_load_html_response) 2011-10-18 2012-10-18

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IN2592CHN2014 IN2014CN02592A (enrdf_load_html_response) 2011-10-18 2012-10-18

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN2527CHN2014 IN2014CN02527A (enrdf_load_html_response) 2011-10-18 2012-10-18

Country Status (28)

Country Link
US (21) US10293049B2 (enrdf_load_html_response)
EP (6) EP2768532A4 (enrdf_load_html_response)
JP (6) JP6104922B2 (enrdf_load_html_response)
KR (7) KR20140091707A (enrdf_load_html_response)
CN (6) CN103998061A (enrdf_load_html_response)
AR (6) AR088381A1 (enrdf_load_html_response)
AU (6) AU2012326082B2 (enrdf_load_html_response)
BR (6) BR112014009146A8 (enrdf_load_html_response)
CA (6) CA2851651A1 (enrdf_load_html_response)
CY (1) CY1121843T1 (enrdf_load_html_response)
DK (1) DK2768525T3 (enrdf_load_html_response)
EA (6) EA028520B1 (enrdf_load_html_response)
ES (1) ES2734070T3 (enrdf_load_html_response)
HK (3) HK1200722A1 (enrdf_load_html_response)
HR (1) HRP20191215T1 (enrdf_load_html_response)
HU (1) HUE045624T2 (enrdf_load_html_response)
IL (6) IL231824A0 (enrdf_load_html_response)
IN (3) IN2014CN02592A (enrdf_load_html_response)
LT (1) LT2768525T (enrdf_load_html_response)
MX (7) MX367054B (enrdf_load_html_response)
PL (1) PL2768525T3 (enrdf_load_html_response)
PT (1) PT2768525T (enrdf_load_html_response)
RS (1) RS59179B1 (enrdf_load_html_response)
SG (6) SG11201401519RA (enrdf_load_html_response)
SI (1) SI2768525T1 (enrdf_load_html_response)
SM (1) SMT201900422T1 (enrdf_load_html_response)
TW (6) TW201325606A (enrdf_load_html_response)
WO (6) WO2013059407A1 (enrdf_load_html_response)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
BR112014009146A8 (pt) * 2011-10-18 2017-06-20 Coherus Biosciences Inc formulações de etanercepte estabilizadas com aminoácidos
EA029193B1 (ru) * 2012-07-09 2018-02-28 Кохерус Байосайенсис, Инк. Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
KR102133699B1 (ko) * 2012-09-11 2020-07-14 코히러스 바이오사이언시즈, 인코포레이티드 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트
KR20160008575A (ko) * 2013-05-02 2016-01-22 마브사이언스 에스. 에이. ＴＮＦＲ: Ｆｃ 융합 폴리펩티드에 대한 대체 제제
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
EP3892288A1 (en) * 2013-10-24 2021-10-13 Astrazeneca AB Stable, aqueous antibody formulations
EP3073992A4 (en) * 2013-11-29 2017-09-13 Ares Trading S.A. A liquid formulation of a fusion protein comprising tnfr and fc region
IS3008B (is) * 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20180200325A1 (en) * 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
ES2833506T3 (es) * 2014-12-22 2021-06-15 Ares Trading Sa Composición farmacéutica líquida
US20180256717A1 (en) * 2014-12-23 2018-09-13 Drug Discovery Laboratory As Protein compositions and use thereof
RU2670166C1 (ru) * 2014-12-31 2018-10-18 ЭлДжи КЕМ, ЛТД. Способ получения слитого белка tnfr-fc с заданным содержанием примесей
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN105748414A (zh) * 2016-03-02 2016-07-13 张光泉 抗感染米卡芬净冻干组合物及其制备方法
WO2017179683A1 (ja) * 2016-04-15 2017-10-19 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ミカファンギンの安定化された医薬組成物
KR102413592B1 (ko) * 2016-10-21 2022-06-27 암젠 인크 약학적 제형 및 그의 제조 방법
US11236146B2 (en) 2016-10-28 2022-02-01 Celltrion Inc. Stable pharmaceutical formulation
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
EP3718531A4 (en) * 2017-11-30 2023-08-16 Bio-Thera Solutions, Ltd. LIQUID PREPARATION OF A HUMANIZED ANTIBODY FOR THE TREATMENT OF IL-6-RELATED DISEASES
CN111556744B (zh) * 2017-12-22 2023-12-29 韩商三星Bioepis 股份有限公司 包含vegf拮抗物的液体组合物
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201911461D0 (en) 2019-08-09 2019-09-25 Arecor Ltd Novel composition
JP2023502777A (ja) * 2019-11-26 2023-01-25 コメラ ライフ サイエンシズ，インコーポレイテッド バイオポリマー製剤のための賦形剤化合物
AU2022223669A1 (en) 2021-02-17 2023-08-03 Arecor Limited Aqueous composition of an engineered protein construct comprising an fc domain
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CN1406132A (zh) 2000-02-10 2003-03-26 惠氏公司 处理或抑制细胞损伤或细胞死亡的方法
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
US6936437B2 (en) * 2001-02-23 2005-08-30 Lucia Irene Gonzalez-Villasenor Methods and compositions for production of recombinant peptides
DK1478394T3 (da) * 2002-02-27 2008-10-13 Immunex Corp Stabiliseret TNFR-Fc formulation med arginin
EP1603596B1 (en) * 2003-02-28 2008-05-07 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding protein tbp-1
WO2004082715A1 (ja) 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
WO2005012353A1 (en) 2003-08-01 2005-02-10 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
MXPA06003963A (es) 2003-10-14 2006-08-25 Intermune Inc Acidos carboxilicos macrociclicos y acilsulfonamidas como inhibidores de replicacion del hcv.
WO2005082377A1 (ja) * 2004-03-01 2005-09-09 Ajinomoto Co., Inc. 抗ヒトTNF-α抗体活性低下抑制剤
EP1720972B1 (en) 2004-03-05 2014-01-08 DSM IP Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006132363A1 (ja) * 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
EP1909831A4 (en) * 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
DK1962886T4 (da) 2005-12-20 2022-05-02 Bristol Myers Squibb Co Stabile proteinformuleringer
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
KR20080098504A (ko) 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
EP2024392A2 (en) * 2006-03-17 2009-02-18 Biogen Idec MA, Inc. Stabilized polypeptide compositions
WO2007107340A2 (en) 2006-03-21 2007-09-27 Eugen Oetringer Devices for and methods of analyzing a physiological condition of a physiological subject based on a workload related property
EP2021030A2 (en) 2006-04-21 2009-02-11 Amgen, Inc. Buffering agents for biopharmaceutical formulations
WO2008063717A2 (en) * 2006-08-01 2008-05-29 Illumigen Biosciences, Inc. Pharmaceutical manufacturing methods
EP2081553B1 (en) 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
CL2007002881A1 (es) 2006-10-20 2008-05-09 Amgen Inc Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodo
US8192951B2 (en) 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
WO2008079290A2 (en) 2006-12-21 2008-07-03 Amgen Inc Stable buffered formulations containing polypeptides
PT2115126E (pt) 2007-03-02 2015-08-24 Wyeth Llc Utilização de cobre e glutamato na cultura de células para a produção de polipeptídeos
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
PT2170390T (pt) * 2007-06-14 2019-02-12 Biogen Ma Inc Formulações com anticorpo natalizumab
WO2009073569A2 (en) * 2007-11-30 2009-06-11 Abbott Laboratories Protein formulations and methods of making same
AU2009204863B2 (en) * 2008-01-15 2015-07-16 AbbVie Deutschland GmbH & Co. KG Powdered protein compositions and methods of making same
EA201070987A1 (ru) 2008-02-29 2011-04-29 Байоджен Айдек Ма Инк. Очищенные гибридные белки иммуноглобулина и способы их очищения
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
AU2010282733B2 (en) 2009-08-11 2016-07-14 Genentech, Inc. Production of proteins in glutamine-free cell culture media
WO2011049798A1 (en) 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
US20130052195A1 (en) * 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
USRE48864E1 (en) 2010-04-26 2021-12-28 Novartis Ag Cell culture medium
CN102946858B (zh) * 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
WO2012013980A1 (en) 2010-07-30 2012-02-02 Arecor Limited Stabilized aqueous antibody compositions
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
CA2807895A1 (en) 2010-08-31 2012-03-08 Friesland Brands B.V. Culture medium for eukaryotic cells
AU2011316730B2 (en) 2010-10-11 2015-12-10 Abbvie Bahamas Ltd. Processes for purification of proteins
RU2614257C2 (ru) * 2011-04-20 2017-03-24 Сандоз Аг СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
WO2013003731A2 (en) 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
EP2726090B1 (en) * 2011-07-01 2020-01-01 Biogen MA Inc. Arginine - free tnfr : fc- fusion polypeptide compositions
ES2625045T3 (es) 2011-07-01 2017-07-18 Amgen Inc. Cultivo de células de mamífero
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
CN103814044A (zh) 2011-07-08 2014-05-21 默沙东公司 纯化fc-融合蛋白的方法
US9279014B2 (en) 2011-08-17 2016-03-08 Ares Trading S.A. Methods for preparing an active TNFR-Fc fusion protein
BR112014009146A8 (pt) * 2011-10-18 2017-06-20 Coherus Biosciences Inc formulações de etanercepte estabilizadas com aminoácidos
KR102133699B1 (ko) 2012-09-11 2020-07-14 코히러스 바이오사이언시즈, 인코포레이티드 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트

Also Published As

Publication number Publication date
US10772963B2 (en) 2020-09-15
BR112014009146A2 (pt) 2017-06-13
JP6220788B2 (ja) 2017-10-25
AR088383A1 (es) 2014-05-28
EP2768525A1 (en) 2014-08-27
AR088380A1 (es) 2014-05-28
US11135267B2 (en) 2021-10-05
SG11201401519RA (en) 2014-07-30
US10987405B2 (en) 2021-04-27
HK1200721A1 (en) 2015-08-14
EA025663B1 (ru) 2017-01-30
HK1200851A1 (en) 2015-08-14
SI2768525T1 (sl) 2019-10-30
MX2014004725A (es) 2015-02-05
EA201490815A1 (ru) 2014-09-30
TW201325608A (zh) 2013-07-01
KR20140083037A (ko) 2014-07-03
SG11201401576WA (en) 2014-10-30
US20180193463A1 (en) 2018-07-12
EP2768854A4 (en) 2015-03-11
EP2768535A4 (en) 2015-03-11
US20190314500A1 (en) 2019-10-17
KR20140091706A (ko) 2014-07-22
SG11201401567YA (en) 2014-07-30
IL231824A0 (en) 2014-05-28
JP6199298B2 (ja) 2017-09-20
DK2768525T3 (da) 2019-07-22
BR112014009022A2 (pt) 2017-05-02
CN104010654A (zh) 2014-08-27
KR20140091705A (ko) 2014-07-22
HK1200719A1 (en) 2015-08-14
ES2734070T3 (es) 2019-12-04
JP6110393B2 (ja) 2017-04-05
CN104010658A (zh) 2014-08-27
CY1121843T1 (el) 2020-07-31
EA025267B1 (ru) 2016-12-30
AR088379A1 (es) 2014-05-28
MX2019009176A (es) 2019-10-07
HUE045624T2 (hu) 2020-01-28
IL231825A0 (en) 2014-05-28
US9801942B2 (en) 2017-10-31
CA2851635A1 (en) 2013-04-25
TW201325609A (zh) 2013-07-01
MX2014004733A (es) 2015-05-15
WO2013059412A1 (en) 2013-04-25
EP2768531A4 (en) 2015-03-11
KR102163150B1 (ko) 2020-10-08
JP2014530864A (ja) 2014-11-20
AU2012326082A1 (en) 2014-04-24
BR112014009131A8 (pt) 2017-06-20
JP6104922B2 (ja) 2017-03-29
IL231827A0 (en) 2014-05-28
EP2768525B1 (en) 2019-06-19
CN104010654B (zh) 2017-10-27
JP2014530256A (ja) 2014-11-17
TWI644681B (zh) 2018-12-21
AR088460A1 (es) 2014-06-11
US10213508B2 (en) 2019-02-26
WO2013059408A1 (en) 2013-04-25
HRP20191215T1 (hr) 2019-10-04
TWI595883B (zh) 2017-08-21
EA028520B1 (ru) 2017-11-30
US20160317667A1 (en) 2016-11-03
US9302002B2 (en) 2016-04-05
SG11201401563SA (en) 2014-09-26
TW201325606A (zh) 2013-07-01
IL231826A0 (en) 2014-05-28
US20160199489A1 (en) 2016-07-14
EA201490803A1 (ru) 2014-09-30
US20190216930A1 (en) 2019-07-18
EA201490817A1 (ru) 2014-09-30
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
US9770510B2 (en) 2017-09-26
JP2014530862A (ja) 2014-11-20
SG11201401517VA (en) 2014-09-26
MX2014004728A (es) 2015-05-15
US20190314499A1 (en) 2019-10-17
SG11201401562RA (en) 2014-09-26
EP2768533A4 (en) 2015-03-11
AU2012326080A1 (en) 2014-04-24
MX2014004732A (es) 2015-05-15
AU2012326082B2 (en) 2016-12-15
CN104011073A (zh) 2014-08-27
AU2012326084B2 (en) 2016-12-15
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (en) 2013-04-25
WO2013059407A1 (en) 2013-04-25
MX2014004726A (es) 2015-05-15
HK1200722A1 (en) 2015-08-14
US20130108633A1 (en) 2013-05-02
AU2012326168B2 (en) 2016-12-15
AR088381A1 (es) 2014-05-28
SMT201900422T1 (it) 2019-09-09
TW201325610A (zh) 2013-07-01
PL2768525T3 (pl) 2019-10-31
MX367054B (es) 2019-08-02
IL231828A0 (en) 2014-05-28
US20190290767A1 (en) 2019-09-26
EP2768531A1 (en) 2014-08-27
EP2768525A4 (en) 2015-07-15
EA027325B1 (ru) 2017-07-31
US11129876B2 (en) 2021-09-28
CA2851651A1 (en) 2013-04-25
CN103998060A (zh) 2014-08-20
EA201490801A1 (ru) 2014-09-30
KR20200008021A (ko) 2020-01-22
CN104010657A (zh) 2014-08-27
LT2768525T (lt) 2019-09-25
CA2851639A1 (en) 2013-04-25
CA2851642A1 (en) 2013-04-25
AU2012326084A1 (en) 2014-04-17
US20190290766A1 (en) 2019-09-26
AU2012326171A1 (en) 2014-04-24
CA2851646A1 (en) 2013-04-25
TW201325611A (zh) 2013-07-01
TWI619504B (zh) 2018-04-01
MX2014004734A (es) 2015-05-15
IN2014CN02592A (enrdf_load_html_response) 2015-09-04
EP2768533A1 (en) 2014-08-27
US20180125982A1 (en) 2018-05-10
JP2014530863A (ja) 2014-11-20
AU2012326171B2 (en) 2017-03-09
AU2012326170B2 (en) 2016-12-22
KR20140097184A (ko) 2014-08-06
JP2014530254A (ja) 2014-11-17
BR112014009087A2 (pt) 2017-04-18
JP6220789B2 (ja) 2017-10-25
US10376588B2 (en) 2019-08-13
KR20140091707A (ko) 2014-07-22
BR112014009146A8 (pt) 2017-06-20
US10980884B2 (en) 2021-04-20
EA201490802A1 (ru) 2014-08-29
IL231829A0 (en) 2014-05-28
EP2768532A1 (en) 2014-08-27
EA026410B1 (ru) 2017-04-28
EP2768535A1 (en) 2014-08-27
CN104011073B (zh) 2017-08-25
EP2768854A1 (en) 2014-08-27
US20190290765A1 (en) 2019-09-26
US10980885B2 (en) 2021-04-20
RS59179B1 (sr) 2019-10-31
AR088382A1 (es) 2014-05-28
US20190290768A1 (en) 2019-09-26
CA2851639C (en) 2020-12-29
US20130101640A1 (en) 2013-04-25
IN2014CN02527A (enrdf_load_html_response) 2015-06-26
EA201490804A1 (ru) 2014-09-30
PT2768525T (pt) 2019-07-17
US9943601B2 (en) 2018-04-17
US20130108632A1 (en) 2013-05-02
US20190314498A1 (en) 2019-10-17
KR102068462B1 (ko) 2020-01-22
BR112014009031A2 (pt) 2017-05-09
EP2768532A4 (en) 2015-03-11
BR112014009073A2 (pt) 2017-05-09
AU2012326168A1 (en) 2014-04-24
AU2012326170A1 (en) 2014-04-24
TW201325607A (zh) 2013-07-01
US20130101584A1 (en) 2013-04-25
BR112014009131A2 (pt) 2017-06-13
HK1200718A1 (en) 2015-08-14
US20190184017A1 (en) 2019-06-20
WO2013059406A1 (en) 2013-04-25
US20190328875A1 (en) 2019-10-31
WO2013059405A1 (en) 2013-04-25
CN103998060B (zh) 2016-12-21
US10888619B2 (en) 2021-01-12
CN103998061A (zh) 2014-08-20
CA2851628A1 (en) 2013-04-25
JP6113176B2 (ja) 2017-04-12
AU2012326080B2 (en) 2017-02-16
US20200405865A1 (en) 2020-12-31
JP2014530255A (ja) 2014-11-17
US20190298837A1 (en) 2019-10-03
HK1200720A1 (en) 2015-08-14
KR20140079491A (ko) 2014-06-26

Similar Documents

Publication Publication Date Title
IN2014CN02591A (enrdf_load_html_response)
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
EP4378959A3 (en) Formulation for anti-alpha4beta7 antibody
PH12014502778B1 (en) Antibody formulation
MX2016009666A (es) Suministro topico de composiciones para la piel que tienen ph bajo.
EP4378484A3 (en) Formulation for anti-alpha4beta7 antibody
MX340463B (es) Formulaciones liquidas para un conjugado de g-csf de accion prolongada.
WO2012076670A3 (en) Antibody formulation
PH12013500372A1 (en) Dexmedetomidine premix formulation
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
WO2014076569A3 (en) Controlled release topical testosterone formulations and methods
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
MX2012002861A (es) Formulaciones farmaceuticas muy concentradas.
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
GEP20146177B (en) Pyrazole compounds as crth2 antagonists
PH12014501937A1 (en) Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
JP2013518051A5 (enrdf_load_html_response)
HK1223559A1 (zh) 用於促性腺激素的配方
NZ707168A (en) Pharmaceutical composition of insulins
EA201591218A1 (ru) Способы и композиции для введения оксибутинина
WO2012157921A3 (ko) 리바스티그민 또는 이의 염을 함유하는 경피 투여 조성물
TH142232A (th) องค์ประกอบสารกันแดดที่เสถียร
TN2013000442A1 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY